TrialPath
Recruiting

A Study to Evaluate ATX-898 in Participants With Advanced Solid Tumors

NCT07767474 · Antares Therapeutics, Inc
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
First-in-human Study of ATX-898, as Monotherapy and in Combination With Other Anti-neoplastic Agents, in Participants With Advanced Solid Tumors
About this study
Study ATX-898-101 is a phase 1/2 open-label study evaluating the safety, tolerability, pharmacokinetic, and preliminary efficacy of ATX-898 as monotherapy and in combination with anti-neoplastic agents in selected solid tumors. This study consists of 2 parts. Part 1 evaluates ATX-898 as monotherapy and Part 2 evaluates ATX-898 in combination with anti-neoplastic agents of interest. Both parts will consists of a dose escalation portion and a dose expansion portion.
Eligibility criteria
Inclusion Criteria: * Has histologically or cytologically confirmed advanced solid tumor malignancy that is metastatic or locally advanced and unresectable * Is ≥18 years of age at the time of signing the informed consent form * ECOG performance status score of 0 or 1 * Adequate organ function * Must consent to a pre-treatment tumor biopsy (collected during screening or have available archival tumor tissue in the past 5 years. For Part 1a (monotherapy dose escalation) * Has received one or more standard systemic therapies and additional standard therapies are either not available, or participant ineligible for available standard therapies For Part 1b (monotherapy dose expansion) * b1: Has platinum-resistant or refractory metastatic ovarian cancer * b2: Has recurrent or metastatic gynecologic cancer excluding the cancers eligible for b1 * b3: Has recurrent advanced or metastatic solid tumor excluding the cancers eligible for b1 or b2 * Has at least 1 measurable lesion per RECIST 1.1 For Part 2a (combination dose escalation) * Has confirmed HR+ HER2 - (including HER2 low and ultra low) status * Has received prior therapy in the metastatic For Part 2b (combination dose expansion) * Has confirmed HR+ HER2 - (including HER2 low and ultra low) status * Treatment-naïve or has received prior therapy in the metastatic setting Exclusion Criteria: * Has history (within ≤2 years before screening) of a solid tumor or hematological malignancy that is histologically distinct from the cancer being studied * Has symptomatic CNS metastases at screening or asymptomatic CNS metastases requiring corticosteroids to control symptoms within 28 days prior to the first dose of ATX-898. * Has toxicities from previous anticancer therapies that have not resolved to baseline levels or to CTCAE Grade ≤1, with the exception of alopecia any grade and Grade ≤2 peripheral neuropathy * Has any condition for which, in the opinion of the Investigator, participation would not be in the best interest of the participant or would prevent, limit, or confound the protocol-specified assessments Cohort Specific: * For abemaciclib cohorts only: has a history of any events of cardiac etiology that would contraindicate dosing with abemaciclib * For ribocicilib only: has history of pneumonitis or interstitial lung disease
Study design
Enrollment target: 343 participants
Allocation: non_randomized
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2026-08-31
Estimated completion: 2030-01-31
Last updated: 2026-10-16
Interventions
Drug: ATX-898Drug: ATX-898Drug: ATX-898Drug: ATX-898Drug: ATX-898Drug: ATX-898, fulvestrant, ribociclibDrug: ATX-898, fulvestrant, ribociclibDrug: ATX-898, fulvestrant, ribociclib
Primary outcomes
  • • Part 1a monotherapy dose escalation - Occurrence of Dose limiting toxicities (DLTs) (12 months)
  • • Part 1a monotherapy dose escalation - Maximally tolerated/tested dose (MTD) (12 months)
  • • Part 1a monotherapy dose escalation - Recommended dose for expansion (RDE) (12 months)
Sponsor
Antares Therapeutics, Inc · industry
Contacts & investigators
ContactAntares Medical Monitor · contact · clinicaltrials@antaresrx.com · +1 781-288-5760
All locations (6)
START Dallas Fort Worth Cancer CenterRecruiting
Fort Worth, Texas, United States
MD Anderson Cancer CenterRecruiting
Houston, Texas, United States
START San Antonio Cancer CenterRecruiting
San Antonio, Texas, United States
START Mountain Region Cancer CenterRecruiting
West Valley City, Utah, United States
NEXT Virginia Cancer Center- Merrifield Tech CenterRecruiting
Fairfax, Virginia, United States
Linear Clinical ResearchRecruiting
Perth, Western Australia, Australia
A Study to Evaluate ATX-898 in Participants With Advanced Solid Tumors · TrialPath